Acetazolamide treatment in late onset CDG type 1 due to biallelic pathogenic DHDDS variants

Jehan Mousa, Larissa Veres, Anab Mohamed, Diederik De Graef, Eva Morava

Research output: Contribution to journalArticlepeer-review


Pathogenic variants in DHDDS have been associated with either autosomal recessive retinitis pigmentosa or DHDDS-CDG. Heterozygous variants in DHDDS have been described in patients with a progressive neurodegenerative disease. Here we report on an individual presenting with a multisystem CDG phenotype who was diagnosed with known homozygous pathogenic DHDDS variants, previously associated with isolated retinitis pigmentosa. An adult Ashkenazi Jewish female developed multiple symptoms of late onset type 1 CDG including seizures, ataxia, protein losing enteropathy, tremor, and titubation in association with elevated mono-oligo/di-oligo transferrin ratio in blood, and classic retinitis pigmentosa. She was diagnosed by whole exome sequencing with the common Ashkenazi Jewish, homozygous p.K42E variants in DHDDS. She was started on Acetazolamide and responded well to the treatment which improved her titubation, tremor, and generalized edema. Reviewing the literature, families with DHDDS variants and multisystem presentation were different from our patient's presentation in terms of clinical manifestations, severity, genetic defect, and mode of inheritance. In previously reported patients with neurologic symptoms including seizures, movement abnormalities, and global development delay, the phenotype was caused by heterozygous pathogenic variants in DHDDS. The infant who was reported with a multisystem phenotype and fatal type 1 CDG had compound heterozygosity for a nonsense and a splice site variant in DHDDS, resulting in DHDDS-CDG. The discovery of the novel phenotype associated with the common p.K42E pathogenic variant in DHDDS expands the spectrum of CDG and further enhances our understanding on the role of DHDDS in glycosylation beyond the retina.

Original languageEnglish (US)
Article number100901
JournalMolecular Genetics and Metabolism Reports
StatePublished - Sep 2022


  • Acetazolamide
  • Ataxia
  • Glycosylation
  • Intrafamilial variability
  • Retinitis pigmentosa
  • Seizures

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Endocrinology


Dive into the research topics of 'Acetazolamide treatment in late onset CDG type 1 due to biallelic pathogenic DHDDS variants'. Together they form a unique fingerprint.

Cite this